Aerie Pharmaceuticals price target raised to $86 from $76 at Needham. Needham analyst Serge Belanger raised his price target on Aerie Pharmaceuticals to $86 and kept his Buy rating after hosting investor meetings with its management. The analyst says the company has provided “anecdotal feedback” of a strong initial launch of Rhopressa, with physicians reporting efficacy levels superior to those observed in the clinical trials along with lower incidences of hyperemia. Belanger notes that the management is “increasingly confident” about meeting its $20M-$30M sales guidance for 2018 and “comfortable” with consensus estimates for revenue in FY19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.